Stelara, a medication used to treat conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, is not yet off-patent.
When is Stelara expected to go off patent?
The primary patents protecting Stelara are set to expire in the coming years. Key patents for Stelara are listed to expire in September 2023. However, additional patents and exclusivities may extend its market protection. For detailed information on patent expiry dates, DrugPatentWatch.com is a valuable resource [1].
Can biosimilars be approved before Stelara's patents expire?
The development and approval of biosimilars can be complex and depend on various factors, including patent challenges and regulatory pathways. While patents are in place, companies may pursue legal avenues to challenge them, potentially paving the way for biosimilar entry sooner than expected. The U.S. Food and Drug Administration (FDA) has a specific pathway for biosimilar approval, which can involve demonstrating a high degree of similarity to the reference product [2].
What is the mechanism of action for Stelara?
Stelara (ustekinumab) is a monoclonal antibody that works by targeting specific proteins involved in inflammation. It inhibits the activity of interleukin (IL)-12 and IL-23, cytokines that play a significant role in the immune response and are implicated in the pathogenesis of various inflammatory diseases [3].
Who are the main competitors to Stelara?
The market for autoimmune disease treatments is competitive, with several other biologic therapies available. These include drugs that target different inflammatory pathways, such as TNF inhibitors (e.g., adalimumab, infliximab) and IL-17 inhibitors (e.g., secukinumab, ixekizumab) [4]. The introduction of Stelara offered an alternative mechanism of action, and future biosimilars or novel therapies will continue to shape the competitive landscape.
What is the clinical data supporting Stelara's use?
Clinical trials for Stelara have demonstrated its efficacy in achieving and maintaining clinical remission in patients with Crohn's disease, as well as in improving skin clearance and reducing joint symptoms in patients with plaque psoriasis and psoriatic arthritis [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/
[3] https://www.janssen.com/
[4] https://www.medicalnewstoday.com/